Jcr Pharmaceuticals Sustainability Profile
JCR Pharmaceuticals Co., Ltd., commonly referred to as JCR Pharma, is a leading biopharmaceutical company headquartered in Japan. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of rare diseases and regenerative medicine. With a strong focus on enzyme replacement therapies and gene therapies, JCR Pharma is renowned for its unique products that address unmet medical needs. The company operates primarily in Japan, with expanding influence in international markets. Notable achievements include the successful launch of its flagship products, which have positioned JCR Pharma as a key player in the biopharmaceutical industry. Through its commitment to research and development, JCR Pharmaceuticals continues to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Jcr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jcr Pharmaceuticals's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jcr Pharmaceuticals's reported carbon emissions
In 2023, JCR Pharmaceuticals reported total carbon emissions of approximately 14,255,621,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 14,255,621,000 kg CO2e. Scope 1 emissions were reported at about 4,472,000 kg CO2e, while Scope 2 emissions totalled approximately 4,368,000 kg CO2e. The combined total for Scope 1 and Scope 2 emissions was about 7,499,000 kg CO2e. In 2022, the company reported Scope 1 emissions of approximately 3,315,000 kg CO2e and Scope 2 emissions of about 5,266,000 kg CO2e in Japan, with global Scope 1 emissions at approximately 5,411,000 kg CO2e and Scope 2 emissions at about 4,586,000 kg CO2e. JCR Pharmaceuticals has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions for Scope 1 and Scope 2 by 2030, as part of the SuMi TRUST Group Carbon Neutral Commitment announced in October 2021. The company is actively working to assess and disclose climate-related risks in line with TCFD recommendations and is focused on calculating the greenhouse gas emissions across its entire supply chain. Overall, JCR Pharmaceuticals is committed to reducing its carbon footprint and enhancing transparency in its climate-related initiatives, reflecting a proactive approach to sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,432,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 29,243,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000,000 |
How Carbon Intensive is Jcr Pharmaceuticals's Industry?
How Carbon Intensive is Jcr Pharmaceuticals's Location?
Jcr Pharmaceuticals's Scope 3 Categories Breakdown
Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 94% of Scope 3 emissions.
Top Scope 3 Categories
Jcr Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jcr Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
